Monitor enrollment updates and any early safety/efficacy signals from the Corventis trial. The IND clearance removes a key regulatory hurdle but does not de-risk the clinical program; initial data in H2 2027 will be the next major catalyst. Watch for potential capital raises as the company funds the trial.
Price Chart
Executive Summary
Atrium Therapeutics announced FDA clearance of its IND application for ATR 1072, allowing the company to initiate the Corventis Phase 1/2 clinical trial for PRKAG2 syndrome, a rare genetic cardiomyopathy with no approved therapies. This is the company's first precision cardiology program to enter the clinic, with first patient enrollment expected by end of 2026 and initial proof-of-concept data anticipated in H2 2027.
Key Facts
- FDA cleared IND for ATR 1072 for PRKAG2 syndrome
- Corventis Phase 1/2 open-label, multicenter trial will enroll approximately 37 participants
- First participant enrollment expected by end of 2026
- Initial proof-of-concept data anticipated in second half of 2027
- PRKAG2 syndrome affects an estimated 1,000-2,000 people in the US with no approved therapies
Financial Impact
No financial figures provided; company is pre-revenue. Milestone advances lead pipeline candidate but does not change near-term cash burn or revenue outlook.
Risk Factors
- Clinical trial failure or safety issues could halt development
- Slow enrollment in a rare disease with limited patient population
- Need for additional financing to complete the trial and advance pipeline
- Competition from other gene therapy or RNA approaches for cardiomyopathies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (RNA) — Batch item 1 | 0001193125-26-303393 |
| Document: d132402dex991.htm | 0001193125-26-303393 |
| Document: 0001193125-26-303393-index-headers.html | 0001193125-26-303393 |
| Document: 0001193125-26-303393-index.html | 0001193125-26-303393 |
| Document: 0001193125-26-303393.txt | 0001193125-26-303393 |
| 8-K Filing (RNA) — Batch item 6 | 0001193125-26-303393 |
| Document: d132402dex991.htm | 0001193125-26-303393 |
| Document: 0001193125-26-303393-index-headers.html | 0001193125-26-303393 |
| Document: 0001193125-26-303393-index.html | 0001193125-26-303393 |
| Document: 0001193125-26-303393.txt | 0001193125-26-303393 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 5d ago | Press Release | $8.00 | awaiting T+5 | — | $8.05 (+0.63%) |
Oct 9, 2026 17d ago | 8-K/A | $8.40 $7.67 | ▼ −8.69% | ▼ −6.72% | $8.05 (−4.17%) |
Oct 8, 2026 18d ago | 8-K | $8.26 $7.82 | ▲ +5.33% | ▲ +5.05% | $8.05 (+2.54%) |
Sep 21, 2026 4w ago | Press Release | $9.22 $8.42 | ▼ −8.68% | ▼ −7.49% | $8.05 (−12.69%) |
Aug 20, 2026 9w ago | Press Release | $13.20 $13.64 | ▲ +3.33% | ▲ +2.86% | $8.05 (−39.02%) |
Aug 13, 2026 10w ago | 8-K | $12.84 $13.20 | ▲ +2.80% | ▲ +4.17% | $8.05 (−37.31%) |
Aug 13, 2026 10w ago | Press Release | $12.84 $13.20 | ▲ +2.80% | ▲ +4.17% | $8.05 (−37.31%) |
Jul 20, 2026 13w ago | Press Release | $12.29 $11.57 | ▼ −5.86% | ▼ −4.63% | $8.05 (−34.50%) |
Jul 14, 2026 14w ago | 8-K | $12.30 $12.17 | ▼ −1.06% | ▼ −0.08% | $8.05 (−34.55%) |
May 14, 2026 23w ago | 8-K | $13.23 $13.09 | ▼ −1.06% | ▼ −2.02% | $8.05 (−39.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers